Tracer library / [177Lu]Lu-cAC10

[177Lu]Lu-cAC10

Also written as [Lu-177]Lu-cAC10

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Lymphoma Preclinical only, no clinical indication yet

What it is

Compound class: Anti-CD30 monoclonal antibody conjugated with DOTA (radioimmunoconjugate)
Target / mechanism: CD30 receptor, overexpressed in lymphomas PMID 40456588
Clinical application: CD30-positive lymphomas / T-cell lymphomas PMID 40456588
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	>90%	cAC10 antibody conjugated with p-SCN-Bn-DOTA Macrocyclics	40456588 2025 J Nucl Med Conjugation of the antibody to DOTA was performed by incubation with p-SCN-Bn-DOTA (Macrocyclics).

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Macrocyclics
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-cAC10, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40456588. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40456588: 'cAC10 antibody (IgG1 κ) was produced by Proteogenix. Conjugation of the antibody to DOTA was performed by incubation with p-SCN-Bn-DOTA (Macrocyclics).'. Stage set/updated at stage 39 from PMID 40456588: 'The biodistribution, dosimetry, and therapeutic effect of both radioimmunoconjugates were studied in a xenograft mouse model.'.